APELLIS PHARMACEUTICALS INC (APLS) Stock News
NASDAQ:APLS - Nasdaq - US03753U1060 - Common Stock - Currency: USD
APLS Latest News, Press Relases and Analysis
Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should Know
Rhythm Pharmaceuticals (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: RYTM
Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results
Why Acadia Healthcare Company, Inc. (ACHC) is Among the Best Oversold NASDAQ Stocks to Buy Right Now
We recently published a list of 11 Oversold NASDAQ Stocks to Buy Right Now. In this article, we are going to take a look at where Acadia Healthcare Company, Inc. (NASDAQ:ACHC) stands against other oversold NASDAQ stocks to buy right now. On April 28, Darrell Cronk, Wells Fargo Wealth and Investment Management CIO, appeared on […]
Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: ARVN
Qualcomm reinstated, Arista upgraded: Wall Street's top analyst calls
Qualcomm reinstated, Arista upgraded: Wall Street's top analyst calls
Why Stellantis N.V. (STLA) Lagged Performance on Wednesday
We recently published an article titled These 10 Firms Led Lagged Performance on Wednesday. In this article, we are going to take a look at where Stellantis N.V. (NYSE:STLA) stands against the other stocks. Wall Street’s major indices finished in the green territory anew on Wednesday as worries about tariff policies and the Federal Reserve’s independence […]
Why Super Micro Computer Stock Is Soaring Today
Super Micro Computer (NASDAQ: SMCI) stock is rocketing higher Wednesday in response to multiple positive catalysts. At the same point in the session, the S&P 500 had risen 1.8%, and the Nasdaq Composite was up 2.9%. Supermicro's valuation is climbing today thanks to a combination of encouraging developments on the macroeconomic front.
Is Apellis Pharmaceuticals, Inc. (APLS) Among the Best Guru Stocks to Buy According to Wall Street Analysts?
We recently published a list of 11 Best Guru Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stands against other Guru stocks to invest in. Wall Street seems to be breathing a little easier after the initial panic over […]
Apellis Announces Craig Wheeler to Join the Board of Directors
WALTHAM, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that Craig Wheeler, founder and chief...
Apellis Announces Craig Wheeler to Join the Board of Directors
Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
PDUFA target action date is July 28, 2025 WALTHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today...
Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
Reported $781.4 million in full year 2024 revenues, representing 97% year-over-year growth SYFOVRE® (pegcetacoplan injection) full year 2024 net product...
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference
WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 10:30 a.m. ET.
Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference
Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN
WALTHAM, Mass. and STOCKHOLM, Sweden, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today announced...
Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN
Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
WALTHAM, Mass., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference...
Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that the company approved the grant of...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)
WALTHAM, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that the Therapeutic Goods Administration...
Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)
Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference
Reports $709 million in preliminary1 full-year 2024 U.S. net product revenues $611 million in SYFOVRE® U.S. net product revenues, including $167 million in...
Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference
Apellis Announces Keli Walbert to Join the Board of Directors
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in...